The Quantellect read.As of Nov 19, 2026, 11 active firms cover Olema Pharmaceuticals Inc: 10 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $30.00 to $59.00, a moderate spread. The average target of $41.00 sits 480% above the current $7.07. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.70 next quarter toward $-2.90 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy1091%
Neutral19%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$41.00
+479.9% upside
Average target across 6 active firms as of Nov 19, 2026 vs $7.07 current
Highest Target$59.00
Average Target$41.00
Lowest Target$30.00
Detailed analyst forecasts for OLMA
Showing 1–7 of 7 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 10 of 11 active firms rate OLMA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OLMA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.70
Range $-0.81 – $-0.63 · 9 analysts · +41% YoY
Next period, 9 analysts expect Olema Pharmaceuticals Inc to earn $-0.70 a share (range $-0.81 – $-0.63), versus $-0.50 a year earlier. Full-year consensus is $-2.56, growing to $-2.90 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $13.7M next year.
Top analysts covering Olema Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OLMA.
#1
Anupam Rama
JP Morgan · Rank #171
Buy
No targeton OLMA
Overall win rate
48%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$59.00+734.5% to target
Overall win rate
38%
+ Follow
#3
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$36.00+409.2% to target
Overall win rate
24%
+ Follow
#4
RL
Richard Law CFA
Goldman Sachs
Buy
$18.00+154.6% to target
Coverage
—
+ Follow
#5
LP
Laura Prendergast
Stifel
Buy
$30.00+324.3% to target
Coverage
—
+ Follow
OLMA stock forecast FAQ
What is OLMA's average 12-month price target?+
The 6 active firms with a live target average $41.00 for Olema Pharmaceuticals Inc over the next 12 months, ranging from a $59.00 high to a $30.00 low, as of Nov 19, 2026.
Is OLMA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OLMA?+
The Street-high target is $59.00 (Citigroup), and the Street-low is $30.00 (Stifel). The average of all 6 active-firm targets is $41.00.
How many active Wall Street firms cover OLMA?+
11 active firms have a recognized rating on Olema Pharmaceuticals Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OLMA?+
Among analysts who currently cover OLMA, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #171). Their current call is Buy.
What is Olema Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.70 per share (range $-0.81 – $-0.63) across 9 analysts. Full-year EPS is projected at $-2.56, rising to $-2.90 the following year.
How much revenue is Olema Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $13.7M next year.
Have analysts been upgrading or downgrading OLMA lately?+
As of Nov 19, 2026, 10 of 11 active firms rate OLMA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OLMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.